• Developing global, high-value products for patients with significant unmet medical needs in niche indications

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.


A potential treatment for patients with IgA nephropathy at risk of developing ESRD.


Calliditas shortlisted in two categories at the European Lifestars Awards: Post-IPO Equity Raise of the Year and Deal of the Year (<£500m)

Share price Sweden

Share price US

Interim Report Q1 2020

On May 14, 2020, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2020.